What is BPC-157?
BPC-157 is a synthetic pentadecapeptide of 15 amino acids, derived from the sequence of a protein called Body Protection Compound (BPC), isolated from human gastric juice. Predrag Sikiric's laboratory at the University of Zagreb Medical School first identified and characterized it in the early 1990s during investigations into the stomach's cytoprotective mechanisms.
The compound has two properties that make it unusual among research peptides. It is stable in gastric acid: unlike most peptide biologics that degrade on contact with digestive enzymes, BPC-157 retains its structure across a wide pH range. It also appears active at low concentrations, with published studies using doses measured in micrograms or nanograms per kilogram of body weight in animal models.
In research settings, BPC-157 is supplied as a lyophilized (freeze-dried) white powder and requires reconstitution in bacteriostatic water before injection. It has no approved pharmaceutical indication in any major regulatory jurisdiction as of mid-2026. All published human data comes from early-phase trials and one small retrospective case series.
Proposed mechanisms of action
BPC-157 research has identified several overlapping mechanisms across in vitro and in vivo models. None has been fully characterized in human tissue, and the relative contribution of each pathway to observed effects in whole animals remains under investigation.
The best-characterized pathway involves angiogenesis. A 2017 study by Hsieh et al., published in the Journal of Molecular Medicine (Hsieh et al. 2017, in vitro and rat hind limb ischemia model), showed that BPC-157 increased VEGFR2 (vascular endothelial growth factor receptor 2) expression and promoted its internalization in human vascular endothelial cells. This activated the downstream VEGFR2-Akt-eNOS signaling cascade. In rats with surgically induced hind limb ischemia, BPC-157-treated animals showed faster blood flow recovery by laser Doppler scanning and increased vessel density on histological analysis compared to controls.
A 2009 study by Brcic et al. in the Journal of Physiology and Pharmacology (Brcic et al. 2009, rat tendon and muscle healing model) examined VEGF expression during active repair of crushed and transected muscle and tendon tissue in rats. Applying BPC-157 directly to cell cultures produced no measurable angiogenic response. In healing tissue in vivo, immunohistochemical analysis with VEGF, CD34, and Factor VIII antibodies showed elevated vascular marker expression in treated animals. The authors concluded that BPC-157's pro-angiogenic effect is context-dependent and emerges specifically in the repair microenvironment rather than in quiescent tissue.
A parallel line of research focuses on fibroblast behavior. A 2011 study by Chang et al. in the Journal of Applied Physiology (Chang et al. 2011, rat Achilles tendon fibroblast cultures) found that BPC-157 significantly accelerated outgrowth of tendon explants and improved fibroblast survival under hydrogen peroxide-induced oxidative stress. Cell proliferation itself was not directly affected, but migration increased in a dose-dependent manner. The study identified phosphorylation of focal adhesion kinase (FAK) and its scaffolding protein paxillin as the downstream mechanism for the migration effect.
A 2014 study by Chang, Tsai, Hsu, and Pang in Molecules (Chang et al. 2014, in vitro tendon fibroblasts) found that BPC-157 dose- and time-dependently increased growth hormone receptor (GHR) expression in tendon fibroblasts at both the mRNA and protein level. When growth hormone was subsequently added to BPC-157-conditioned cells, proliferation increased as measured by MTT assay, and JAK2 downstream activation was confirmed by Western blot. The authors proposed that BPC-157 may amplify the proliferative effect of circulating growth hormone in fibroblast populations by expanding the available receptor count.
Multiple papers from the Sikiric group describe BPC-157 as a modulator of the nitric oxide system, able to oppose NO-mediated tissue toxicity while preserving NO's cytoprotective functions depending on tissue context. This bidirectional modulation is proposed as the unifying explanation for the peptide's apparent activity across disparate tissue types, though the molecular detail at this level remains largely descriptive and has not been independently replicated to the same degree as the VEGFR2 work.
What the animal evidence shows
Most BPC-157 research uses rat in vivo models. Published studies cover tendon and ligament repair (Achilles detachment, quadriceps reattachment, medial collateral ligament transection), GI tract protection (gastric ulcer induction, bowel anastomosis healing, acetic acid and cysteamine colitis), bone fracture healing, skeletal muscle injury, and neurological injury including spinal cord transection. The diversity of tissue types studied is wider than for most peptides at a comparable stage of development.
That breadth comes with a caveat that appears consistently in independent assessments: more than 80% of BPC-157 publications on PubMed trace back to Sikiric's laboratory at the University of Zagreb. This is not unusual for a niche compound where one group does the foundational work, but it means that the apparent effect sizes in the literature may reflect lab-specific factors such as animal housing conditions, blinding quality, and measurement protocols. An independent replication program would resolve this uncertainty, and that data does not yet exist in published form.
A 2025 systematic review by Vasireddi, Hahamyan, Salata et al. in HSS Journal (Vasireddi et al. 2025, systematic review through June 2024) searched PubMed, Cochrane, and Embase for orthopedic literature on BPC-157. The review confirmed consistent positive outcomes in animal models of musculoskeletal tissue repair. It identified only one human clinical study: a retrospective series of 12 patients with chronic knee pain who received a single intra-articular BPC-157 injection, of whom 7 reported sustained relief lasting over six months. The authors noted that the complete absence of randomized controlled trials in humans prevents any efficacy conclusions for clinical use.
Human trial status
The most advanced human data for BPC-157 comes from a clinical program run by Pliva, a Croatian pharmaceutical company, targeting inflammatory bowel disease. A Phase I safety study in healthy volunteers was presented at Digestive Disease Week 2003 by Veljaca et al. (published as a conference abstract in Gut) and described the compound as safe and well tolerated at the doses studied. That safety signal supported progression to a Phase II study.
The Phase II trial (designation PL-14736) was a multicenter, randomized, double-blind, placebo-controlled study of a BPC-157 enema formulation in patients with mild-to-moderate ulcerative colitis. The trial reportedly demonstrated efficacy. The complete dataset has not been published in a peer-reviewed journal. Conference presentations referenced positive outcomes, but without a full publication the Phase II results cannot be independently verified or subjected to statistical reanalysis. This is the main gap in BPC-157's clinical record.
No Phase III trials have been registered or completed for BPC-157 in any indication as of mid-2026. The Vasireddi et al. systematic review, which searched literature through June 2024, found no completed randomized controlled trials in humans across any therapeutic area.
Practical considerations for research use
BPC-157 is supplied as a lyophilized powder and requires reconstitution before use in research protocols. For a full step-by-step procedure covering sterile technique, injection volume calculation, and bacteriostatic water ratios, see the peptide reconstitution guide. Volume calculations using U-100 insulin syringes are handled by the research dosing calculator.
In published rat studies, BPC-157 has been administered by intraperitoneal, subcutaneous, and intragastric routes. Oral administration is feasible because the peptide is stable in gastric acid. The effective concentration range in Sikiric group systemic protocols is typically 10 micrograms/kg or 10 nanograms/kg body weight. Chang et al. (2011) used 10-8 to 10-6 M in their in vitro fibroblast work. These are research protocol ranges reported in the published literature and are not recommendations for human dosing.
Researchers in Indonesia and Bali face specific storage challenges. Ambient temperatures of 28 to 33°C combined with high relative humidity accelerate peptide degradation in reconstituted form. Lyophilized BPC-157 powder, stored sealed and desiccated at -20°C, is stable for considerably longer than reconstituted solution. Reconstituted solutions should be refrigerated at 2 to 8°C and used within 28 days. Full storage protocol guidance for tropical conditions is in the lyophilized peptide storage guide.
Zurich Biotech supplies BPC-157 as part of the BPC-157 + TB-500 compound line, with HPLC purity testing and a Certificate of Analysis provided with each order. For guidance on interpreting purity figures from a COA, see the peptide purity and COA guide.